These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33365331)

  • 1. Effects of Cardiomyocyte-Specific Deletion of STAT3-A Murine Model of Heart Failure With Preserved Ejection Fraction.
    Zhao W; Chen Y; Yang W; Han Y; Wang Z; Huang F; Qiu Z; Yang K; Jin W
    Front Cardiovasc Med; 2020; 7():613123. PubMed ID: 33365331
    [No Abstract]   [Full Text] [Related]  

  • 2. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.
    van Heerebeek L; Hamdani N; Falcão-Pires I; Leite-Moreira AF; Begieneman MP; Bronzwaer JG; van der Velden J; Stienen GJ; Laarman GJ; Somsen A; Verheugt FW; Niessen HW; Paulus WJ
    Circulation; 2012 Aug; 126(7):830-9. PubMed ID: 22806632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes.
    Mátyás C; Németh BT; Oláh A; Török M; Ruppert M; Kellermayer D; Barta BA; Szabó G; Kökény G; Horváth EM; Bódi B; Papp Z; Merkely B; Radovits T
    Eur J Heart Fail; 2017 Mar; 19(3):326-336. PubMed ID: 27995696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial.
    Scheffer M; Driessen-Waaijer A; Hamdani N; Landzaat JWD; Jonkman NH; Paulus WJ; van Heerebeek L
    ESC Heart Fail; 2020 Dec; 7(6):4478-4487. PubMed ID: 33073523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiomyocyte Functional Etiology in Heart Failure With Preserved Ejection Fraction Is Distinctive-A New Preclinical Model.
    Curl CL; Danes VR; Bell JR; Raaijmakers AJA; Ip WTK; Chandramouli C; Harding TW; Porrello ER; Erickson JR; Charchar FJ; Kompa AR; Edgley AJ; Crossman DJ; Soeller C; Mellor KM; Kalman JM; Harrap SB; Delbridge LMD
    J Am Heart Assoc; 2018 Jun; 7(11):. PubMed ID: 29858360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction.
    Zuo GF; Wang LG; Huang L; Ren YF; Ge Z; Hu ZY; Zhang JJ; Chen SL
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166979. PubMed ID: 38065272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin.
    Zile MR; Baicu CF; Ikonomidis JS; Stroud RE; Nietert PJ; Bradshaw AD; Slater R; Palmer BM; Van Buren P; Meyer M; Redfield MM; Bull DA; Granzier HL; LeWinter MM
    Circulation; 2015 Apr; 131(14):1247-59. PubMed ID: 25637629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator.
    Kolijn D; Kovács Á; Herwig M; Lódi M; Sieme M; Alhaj A; Sandner P; Papp Z; Reusch PH; Haldenwang P; Falcão-Pires I; Linke WA; Jaquet K; Van Linthout S; Mügge A; Tschöpe C; Hamdani N
    Front Physiol; 2020; 11():345. PubMed ID: 32523538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
    Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
    Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.
    Valero-Munoz M; Li S; Wilson RM; Boldbaatar B; Iglarz M; Sam F
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 27810862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Splicing of Titin Restores Diastolic Function in an HFpEF-Like Genetic Murine Model (TtnΔIAjxn).
    Bull M; Methawasin M; Strom J; Nair P; Hutchinson K; Granzier H
    Circ Res; 2016 Sep; 119(6):764-72. PubMed ID: 27470639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction.
    Hamdani N; Bishu KG; von Frieling-Salewsky M; Redfield MM; Linke WA
    Cardiovasc Res; 2013 Mar; 97(3):464-71. PubMed ID: 23213108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
    Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
    Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction.
    van der Pol A; Gil A; Tromp J; Silljé HHW; van Veldhuisen DJ; Voors AA; Hoendermis ES; Grote Beverborg N; Schouten EM; de Boer RA; Bischoff R; van der Meer P
    Cardiovasc Res; 2018 Dec; 114(14):1871-1882. PubMed ID: 30032247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.
    Franssen C; Chen S; Unger A; Korkmaz HI; De Keulenaer GW; Tschöpe C; Leite-Moreira AF; Musters R; Niessen HW; Linke WA; Paulus WJ; Hamdani N
    JACC Heart Fail; 2016 Apr; 4(4):312-24. PubMed ID: 26682792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction.
    Rommel KP; von Roeder M; Latuscynski K; Oberueck C; Blazek S; Fengler K; Besler C; Sandri M; Lücke C; Gutberlet M; Linke A; Schuler G; Lurz P
    J Am Coll Cardiol; 2016 Apr; 67(15):1815-1825. PubMed ID: 27081022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of Na
    Primessnig U; Bracic T; Levijoki J; Otsomaa L; Pollesello P; Falcke M; Pieske B; Heinzel FR
    Eur J Heart Fail; 2019 Dec; 21(12):1543-1552. PubMed ID: 31762174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.
    Mohammed SF; Hussain S; Mirzoyev SA; Edwards WD; Maleszewski JJ; Redfield MM
    Circulation; 2015 Feb; 131(6):550-9. PubMed ID: 25552356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
    Kanagala P; Cheng ASH; Singh A; Khan JN; Gulsin GS; Patel P; Gupta P; Arnold JR; Squire IB; Ng LL; McCann GP
    JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2291-2301. PubMed ID: 30772227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.